Cargando…

In vitro characterisation of [(177)Lu]Lu-DOTA-C595 as a novel radioimmunotherapy for MUC1-CE positive pancreatic cancer

BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) continues to be a malignancy with an unmet clinical demand. Development of radioimmunoconjugates which target cancer-specific receptors provides an opportunity for radioimmunotherapy of both metastatic and primary PDAC. In this study, we characteri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hull, Ashleigh, Hsieh, William, Tieu, William, Bartholomeusz, Dylan, Li, Yanrui, Bezak, Eva
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10425306/ https://www.ncbi.nlm.nih.gov/pubmed/37578571 http://dx.doi.org/10.1186/s41181-023-00204-4

Ejemplares similares

Development of [(225)Ac]Ac-DOTA-C595 as radioimmunotherapy of pancreatic cancer: in vitro evaluation, dosimetric assessment and detector calibration
por: Hull, Ashleigh, et al.
Publicado: (2023)

Preliminary Development and Testing of C595 Radioimmunoconjugates for Targeting MUC1 Cancer Epitopes in Pancreatic Ductal Adenocarcinoma
por: Hull, Ashleigh, et al.
Publicado: (2022)

Intraindividual comparison of [(177)Lu]Lu-DOTA-EB-TATE and [(177)Lu]Lu-DOTA-TOC
por: Hänscheid, Heribert, et al.
Publicado: (2021)

The Expression Profile and Textural Characteristics of C595-Reactive MUC1 in Pancreatic Ductal Adenocarcinoma for Targeted Radionuclide Therapy
por: Hull, Ashleigh, et al.
Publicado: (2020)

Radioimmunotherapy of Pancreatic Ductal Adenocarcinoma: A Review of the Current Status of Literature
por: Hull, Ashleigh, et al.
Publicado: (2020)

First-In-Human Results on the Biodistribution, Pharmacokinetics, and Dosimetry of [(177)Lu]Lu-DOTA.SA.FAPi and [(177)Lu]Lu-DOTAGA.(SA.FAPi)(2)
por: Ballal, Sanjana, et al.
Publicado: (2021)

Individualisation of radiation protection recommendations for patients treated with [(177)Lu]Lu-DOTA-TATE
por: Monserrat Fuertes, Teresa, et al.
Publicado: (2023)

Nephrotoxicity after PRRT with (177)Lu-DOTA-octreotate
por: Bergsma, Hendrik, et al.
Publicado: (2016)

Epidemiology of Neuroendocrine Neoplasms and Results of Their Treatment with [(177)Lu]Lu-DOTA-TATE or [(177)Lu]Lu-DOTA-TATE and [(90)Y]Y-DOTA-TATE—A Six-Year Experience in High-Reference Polish Neuroendocrine Neoplasm Center
por: Durma, Adam Daniel, et al.
Publicado: (2023)

Distinct In Vitro Binding Profile of the Somatostatin Receptor Subtype 2 Antagonist [(177)Lu]Lu-OPS201 Compared to the Agonist [(177)Lu]Lu-DOTA-TATE
por: Mansi, Rosalba, et al.
Publicado: (2021)

Matching-adjusted indirect treatment comparison of [(177)Lu]Lu-DOTA-TATE, everolimus and sunitinib in advanced, unresectable gastroenteropancreatic neuroendocrine tumours: Relative effectiveness of [(177)Lu]Lu-DOTA-TATE in gastroenteropancreatic neuroendocrine tumours
por: Khan, Mohid S., et al.
Publicado: (2021)

Relationships between uptake of [(68)Ga]Ga-DOTA-TATE and absorbed dose in [(177)Lu]Lu-DOTA-TATE therapy
por: Stenvall, Anna, et al.
Publicado: (2022)

Correlations between [(68)Ga]Ga-DOTA-TOC Uptake and Absorbed Dose from [(177)Lu]Lu-DOTA-TATE
por: Bruvoll, Ragnar, et al.
Publicado: (2023)

Radioligand Therapy with [(177)Lu]Lu-DOTA-TATE or [(177)Lu]Lu-DOTA-TATE and [(90)Y]Y-DOTA-TATE in Patients with Neuroendocrine Neoplasms of Unknown Locations, or Locations Other Than the Midgut and Pancreas as Primaries in a G1, G2 and G3 Grade
por: Durma, Adam Daniel, et al.
Publicado: (2023)

Biodistribution and post-therapy dosimetric analysis of [(177)Lu]Lu-DOTA(ZOL) in patients with osteoblastic metastases: first results
por: Khawar, Ambreen, et al.
Publicado: (2019)

Radiation exposure assessment of nuclear medicine staff administering [(177)Lu]Lu-DOTA-TATE with active and passive dosimetry
por: Riveira-Martin, Mercedes, et al.
Publicado: (2023)

In Vivo Measurement and Characterization of a Novel Formulation of [(177)Lu]-DOTA-Octreotate
por: Bailey, Dale L, et al.
Publicado: (2016)

Evaluation of Safety and Dosimetry of (177)Lu-DOTA-ZOL for Therapy of Bone Metastases
por: Fernández, René, et al.
Publicado: (2021)

Comparison of the Anti-Tumour Activity of the Somatostatin Receptor (SST) Antagonist [(177)Lu]Lu-Satoreotide Tetraxetan and the Agonist [(177)Lu]Lu-DOTA-TATE in Mice Bearing AR42J SST(2)-Positive Tumours
por: Plas, Pascale, et al.
Publicado: (2022)

Can the peptide receptor radionuclide therapy [(177)Lu]Lu-DOTA-TATE provide a net benefit for NET patients?
por: Caplin, Martyn E.
Publicado: (2021)

Peptide Receptor Radionuclide Therapy with [(177)Lu]Lu-DOTA-TATE in Patients with Advanced GEP NENS: Present and Future Directions
por: del Olmo-García, Maria I., et al.
Publicado: (2022)

Effects of therapy with [(177)Lu-DOTA(0),Tyr(3)]octreotate on endocrine function
por: Teunissen, Jaap J. M., et al.
Publicado: (2009)

[(177)Lu]Lu-DOTA-ZOL bone pain palliation in patients with skeletal metastases from various cancers: efficacy and safety results
por: Yadav, Madhav Prasad, et al.
Publicado: (2020)

Cellular dosimetry of [(177)Lu]Lu-DOTA-[Tyr(3)]octreotate radionuclide therapy: the impact of modeling assumptions on the correlation with in vitro cytotoxicity
por: Tamborino, Giulia, et al.
Publicado: (2020)

Toxicity of a combined therapy using the mTOR-inhibitor everolimus and PRRT with [(177)Lu]Lu-DOTA-TATE in Lewis rats
por: Zellmer, Johannes, et al.
Publicado: (2020)

Use of [(177)Lu]Lu-DOTA-TATE in the treatment of gastroenteropancreatic neuroendocrine tumours: Results of a UK cost-effectiveness modelling study
por: Glover, Matthew, et al.
Publicado: (2021)

An approach for conjugation of (177)Lu- DOTA-SCN- Rituximab (BioSim) & its evaluation for radioimmunotherapy of relapsed & refractory B-cell non Hodgkins lymphoma patients
por: Thakral, Parul, et al.
Publicado: (2014)

In Vitro Characterization of (177)Lu-DOTA-M5A Anti-Carcinoembryonic Antigen Humanized Antibody and HSP90 Inhibition for Potentiated Radioimmunotherapy of Colorectal Cancer
por: Mohajershojai, Tabassom, et al.
Publicado: (2022)

First preclinical evaluation of [(225)Ac]Ac-DOTA-JR11 and comparison with [(177)Lu]Lu-DOTA-JR11, alpha versus beta radionuclide therapy of NETs
por: Handula, Maryana, et al.
Publicado: (2023)

Practical kidney dosimetry in peptide receptor radionuclide therapy using [(177)Lu]Lu-DOTATOC and [(177)Lu]Lu-DOTATATE with focus on uncertainty estimates
por: Staanum, Peter Frøhlich, et al.
Publicado: (2021)

Matched-pair analysis of [(177)Lu]Lu-PSMA I&T and [(177)Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
por: Hartrampf, Philipp E., et al.
Publicado: (2022)

Kidney absorbed radiation doses for [(177)Lu]Lu-PSMA-617 and [(177)Lu]Lu-PSMA-I&T determined by 3D clinical dosimetry
por: Uijen, Maike J.M., et al.
Publicado: (2023)

Early short-term effects on catecholamine levels and pituitary function in patients with pheochromocytoma or paraganglioma treated with [(177)Lu]Lu-DOTA-TATE therapy
por: Gubbi, Sriram, et al.
Publicado: (2023)

Influence of sampling schedules on [(177)Lu]Lu-PSMA dosimetry
por: Rinscheid, Andreas, et al.
Publicado: (2020)

Extravasation of [(177)Lu]Lu-DOTATOC: case report and discussion
por: Arveschoug, Anne Kirstine, et al.
Publicado: (2020)

Improved quality control of [(177)Lu]Lu-PSMA I&T
por: Kraihammer, Martin, et al.
Publicado: (2023)

Urinary excretion kinetics of [(177)Lu]Lu-PSMA-617
por: de Bakker, Maarten, et al.
Publicado: (2023)

Subacute haematotoxicity after PRRT with (177)Lu-DOTA-octreotate: prognostic factors, incidence and course
por: Bergsma, Hendrik, et al.
Publicado: (2015)

Optimization of (177)Lu-labelling of DOTA-TOC, PSMA-I&T and FAPI-46 for clinical application
por: Cankaya, Aylin, et al.
Publicado: (2023)

Comparative Preclinical Evaluation of HER2-Targeting ABD-Fused Affibody(®) Molecules (177)Lu-ABY-271 and (177)Lu-ABY-027: Impact of DOTA Position on ABD Domain
por: Liu, Yongsheng, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_reien8no5fj86vthfe0om2c8g4